Scilex Holding Co 8-K

What Happened
Scilex Holding Company (SCLX) reported on Form 8‑K that on May 4, 2026 ACEA Therapeutics, Inc. (an indirect, minority‑owned subsidiary of Scilex) entered into a Stock Acquisition Agreement with Phoenix Asia Holdings Limited and ACEA Pharma, Inc. Under the agreement, ACEA Thera will transfer 100% of ACEA Pharma’s common stock to Phoenix Asia in exchange for 100,000,000 newly issued ordinary shares of Phoenix Asia at $10.00 per share (total agreed value $1,000,000,000). Upon closing, ACEA Thera is expected to own approximately 82% of Phoenix Asia. The company also issued a press release on May 4, 2026 announcing the transaction (filed as Exhibit 99.1).

Key Details

• Transaction: Stock Acquisition Agreement dated May 4, 2026 between ACEA Thera, ACEA Pharma and Phoenix Asia.
• Consideration: 100,000,000 Phoenix Asia ordinary shares at $10.00/share = $1,000,000,000 agreed value.
• Ownership: After closing, ACEA Thera expects ~82% ownership of Phoenix Asia.
• Closing conditions: Subject to Hart‑Scott‑Rodino clearance, accuracy of reps/contract compliance (subject to materiality qualifiers), absence of a material adverse effect on ACEA Pharma, and any required Nasdaq approvals; expected to close in Q2 2026 (upon satisfaction or waiver of conditions).
• Disclosure: Full Stock Acquisition Agreement filed as Exhibit 10.1 (certain schedules omitted per Reg S‑K) and press release filed as Exhibit 99.1.

Why It Matters
This is a material corporate transaction that restructures ACEA Pharma under Phoenix Asia and would result in ACEA Thera becoming the majority owner of the combined entity. The $1.0B stock consideration and anticipated ~82% ownership stake are significant for Scilex investors because they affect the ownership and potential strategic positioning of Scilex’s indirect biotech assets. The deal’s completion depends on regulatory clearances (including antitrust review) and Nasdaq determinations, so timing and final outcomes remain contingent on those approvals.